Literature DB >> 2512171

Primary medical therapy for operable breast cancer.

J L Mansi1, I E Smith, G Walsh, R P A'Hern, C L Harmer, H D Sinnett, P A Trott, C Fisher, J A McKinna.   

Abstract

Fifty-seven patients with large but potentially operable primary breast cancer were treated with primary medical therapy rather than initial mastectomy, using chemotherapy (15) or endocrine therapy (42) with the tumour remaining in situ. Of patients treated with chemotherapy, one (7%) achieved a complete remission, and eight (53%) a partial response (overall response rate 60%). Only one patient had progressive disease while on chemotherapy. Of patients who received endocrine therapy, one (2%) achieved a complete response, and 19 (45%) a partial response (overall response rate 47%). Two patients progressed on endocrine therapy. Only 10 patients have so far had a subsequent mastectomy (18%), and 17 (30%) have had radiotherapy and/or conservative surgery. The rest are still on medical therapy. With a median follow-up of 19 months (range 6-42 months) only two patients have had a local recurrence after being disease-free and none have developed uncontrollable local recurrence. Eight (14%) have developed distant metastases and four (7%) have died of metastatic disease. Primary medical therapy may offer an effective alternative to mastectomy for patients with operable breast carcinomas too large for conservative surgery and merits further study.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2512171     DOI: 10.1016/0277-5379(89)90308-8

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  7 in total

Review 1.  Preoperative chemotherapy in operable breast cancer. The influence of timing FEC in relation to surgery.

Authors:  C J van de Velde
Journal:  Drugs       Date:  1993       Impact factor: 9.546

2.  Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial.

Authors:  Masafumi Kurosumi; Yuichi Takatsuka; Toru Watanabe; Shigeru Imoto; Hideo Inaji; Hitoshi Tsuda; Futoshi Akiyama; Goi Sakamoto; Tadashi Ikeda; Shinzaburo Noguchi
Journal:  J Cancer Res Clin Oncol       Date:  2007-12-13       Impact factor: 4.553

Review 3.  Alternative mechanisms of action of anti-oestrogens.

Authors:  A A Colletta; J R Benson; M Baum
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

4.  Conservation surgery after primary chemotherapy in large carcinomas of the breast.

Authors:  U Veronesi; G Bonadonna; S Zurrida; V Galimberti; M Greco; C Brambilla; A Luini; S Andreola; F Rilke; R Raselli
Journal:  Ann Surg       Date:  1995-11       Impact factor: 12.969

5.  Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.

Authors:  E Brain; C Garrino; J L Misset; I G Carbonero; M Itzhaki; E Cvitkovic; E Goldschmidt; F Burki; C Regensberg; E Pappo; R Hagipantelli; M Musset
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Primary systemic therapy for operable breast cancer.

Authors:  E D Anderson; A P Forrest; R A Hawkins; T J Anderson; R C Leonard; U Chetty
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

7.  Intra-arterial chemotherapy in patients with breast cancer: a feasibility study.

Authors:  W G Lewis; V A Walker; H H Ali; J R Sainsbury
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.